Drug Profile
Etanercept biosimilar - Sandoz
Alternative Names: Erelzi; Etanercept-szzs; GP 2015Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Sandoz
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 17 May 2021 The US Supreme Court denies Sandoz's petition to review the Federal Circuit’s decision for etanercept biosimilar
- 17 May 2021 Sandoz intends to launch etanercept biosimilar in multiple chronic autoimmune and inflammatory diseases in USA, in 2029
- 12 Nov 2019 Launched for Ankylosing spondylitis in Spain and Germany (SC) before November